RxDoctor Payments Data

Fiona Eapen

Physician Assistant · Bellmore, NYNPI 1710112289

Payments from drug & device makers

$11,554in general payments, 2019–2025

Across 498 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medimetriks Pharmaceuticals, Inc.$3K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • AbbVie$672
  • Almirall LLC$600
  • LEO Pharma Inc.$565
  • plus $5K from 23 others

What the payments were for

  • Consulting fees$2,75024%
  • Food & beverage$8,32072%
  • Education$4844%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,554 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$51,891
Medicare patients
153
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$62,748
Betamethasone Dipropionate55$2,152
Clindamycin Phosphate22$1,100
Clobetasol Propionate18$1,053
Ketoconazole59$1,019
Fluocinonide24$882
Mometasone Furoate31$720
Alclometasone Dipropionate21$634
Ammonium Lactate26$542
Metronidazole12$494
Mupirocin62$365
ValacyclovirValacyclovir Hcl15$313
Triamcinolone Acetonide47$272
Halobetasol Propionate11$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$382$62,74811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bellmore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →